Start for free
Start for free
Frazier Life Sciences logo

Frazier Life Sciences

North America, Massachusetts, United States, Boston

Description

Frazier Life Sciences invests globally in private and publicly-traded companies that discover and commercialize biopharmaceuticals.

Investor Profile

Frazier Life Sciences has made 7 investments, with 6 in the past 12 months and 43% as lead.

Stage Focus

  • Series A (43%)
  • Series B (29%)
  • Series C (14%)
  • Series D (14%)

Country Focus

  • United States (57%)
  • Germany (14%)
  • Switzerland (14%)
  • The Netherlands (14%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Frazier Life Sciences frequently co-invest with?

Elm Street Ventures
Elm Street Ventures
North America, Connecticut, United States, New Haven
Co-Investments: 1
Canaan Partners
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 1
Access Industries
Access Industries
North America, New York, United States, New York
Co-Investments: 1
Droia Ventures
Droia Ventures
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 2
Connecticut Innovations
Connecticut Innovations
North America, Connecticut, United States, Rocky Hill
Co-Investments: 1
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
Novo Holdings
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 4
Pureos Bioventures
Pureos Bioventures
Europe, Zurich, Switzerland, Küsnacht
Co-Investments: 2
Deep Track Capital
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 2
Jeito Capital
Jeito Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 2

What are some of recent deals done by Frazier Life Sciences?

Hillstar Bio

Boston, Massachusetts, United States

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

BiotechnologyHealth CareMedical
Series AMar 25, 2025
Amount Raised: $67,000,000
Callio Therapeutics

Seattle, Washington, United States

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

BiotechnologyHealth CareMedical
Series AMar 3, 2025
Amount Raised: $187,000,000
Alesta Therapeutics

Leiden, Zuid-Holland, The Netherlands

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology
Series AJan 8, 2025
Amount Raised: $67,301,858
Alentis Therapeutics

Allschwil, Basel-Landschaft, Switzerland

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

BiotechnologyManufacturingPharmaceuticalTherapeutics
Series DNov 12, 2024
Amount Raised: $181,400,000
Halda Therapeutics

New Haven, Connecticut, United States

Halda Therapeutics is a research-stage drug discovery company.

BiotechnologyMedicalTherapeutics
Series BAug 12, 2024
Amount Raised: $126,000,000
Bluejay Therapeutics

San Mateo, California, United States

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

BiotechnologyHealth CarePharmaceutical
Series CMay 9, 2024
Amount Raised: $182,000,000
Tubulis

Munich, Bayern, Germany

Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series BMar 14, 2024
Amount Raised: $139,300,472
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator